Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Glucocorticoid-induced osteoporosis].

J Braun1, J Sieper

  • 1Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne. J.Braun@rheumazentrum-ruhrgebiet.de

Der Orthopade
|August 23, 2001
PubMed
Summary

Steroid therapy significantly increases osteoporosis risk, especially in rheumatoid arthritis patients, leading to bone loss and fractures. Prophylactic treatment with bisphosphonates and vitamin D is crucial for managing this common adverse effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis.

Clinical and experimental rheumatology·2002
Same author

New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Annals of the rheumatic diseases·2002
Same author

[Current status of therapeutic approaches in spondyloarthropathies].

Zeitschrift fur Rheumatologie·2002
Same author

Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin.

Rheumatology (Oxford, England)·2002
Same author

Brain areas specific for attentional load in a motion-tracking task.

Journal of cognitive neuroscience·2002
Same author

Infliximab treatment of severe ankylosing spondylitis: one-year followup.

Arthritis and rheumatism·2002

Area of Science:

  • Rheumatology
  • Endocrinology
  • Bone Metabolism

Background:

  • Steroid-induced osteoporosis is a frequent and serious adverse event in antirheumatic therapy.
  • Greatest bone loss occurs in the first year of steroid intake, primarily affecting the spine.
  • Rheumatoid arthritis patients have a doubled risk of osteoporosis compared to the general population.

Purpose of the Study:

  • To highlight the significant risk of osteoporosis associated with glucocorticoid therapy.
  • To emphasize the need for osteoprotective therapy in rheumatoid arthritis patients undergoing steroid treatment.
  • To advocate for consistent application of prophylactic and therapeutic strategies in clinical practice.

Main Methods:

  • Review of clinical manifestations and risk factors for steroid-induced osteoporosis.
  • Discussion of diagnostic methods including dual-energy X-ray absorptiometry (DXA) and spinal X-rays.
  • Evaluation of therapeutic and prophylactic agents such as bisphosphonates and vitamin D metabolites.

Main Results:

  • Vertebral fractures are common, affecting up to 50% of patients, particularly postmenopausal women.
  • Glucocorticoid therapy independently increases osteoporosis risk, regardless of the underlying disease.
  • Prevalent vertebral fractures predict new fractures, necessitating spinal imaging in patients on long-term steroids.

Conclusions:

  • There is a clear indication for osteoprotective therapy in rheumatoid arthritis patients at risk of steroid-induced osteoporosis.
  • Bisphosphonates and active vitamin D metabolites are key for prophylaxis and treatment.
  • Consistent application of treatment guidelines for steroid-induced osteoporosis is essential despite potential budget constraints.

Related Experiment Videos